Zealand Pharma Announces Final Closing of the License Agreement With Abbott Laboratories on AP214 (ZP1480)
Published: Jun 19, 2012
COPENHAGEN, Denmark, June 19, 2012 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL) announces the final closing of the company's license agreement with Abbott for the development and commercialization of AP214 (referred to as ZP1480 by Zealand Pharma) as described in Company Announcement no. 14-12 on 3 May 2012. The final closing follows the receipt of U.S. Antitrust clearance of the agreement between Action Pharma and Abbott on the acquisition by Abbott of all rights to AP214 from Action Pharma.